Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

462

Figures (1-2)

156

Tables (1-2)

136

Sum=779

Publishing Process of This Article

Item

Count

Browse

Download

Sum=47

Mar 24, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Mar 24, 2025; 16(3): 102076
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.102076

Full Size Figure Download Figure

Figure 1 Consort diagram. mCRC: Metastatic colorectal cancer; WT: Wild-type; EGFR: Epidermal growth factor receptor.

Citation: Pakvisal N, Goldberg RM, Sathitruangsak C, Silaphong W, Faengmon S, Teeyapun N, Teerapakpinyo C, Tanasanvimon S. Overall survival with frontline vs subsequent anti-epidermal growth factor receptor therapies in unresectable, RAS/BRAF wild-type, left-sided metastatic colorectal cancer. World J Clin Oncol 2025; 16(3): 102076
URL: https://www.wjgnet.com/2218-4333/full/v16/i3/102076.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i3.102076